Hims, Novo
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...
Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.
Seaport Research raised the firm’s price target on Hims & Hers to $32 from $28 and keeps a Buy rating on the shares. The company ...
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
uk.investing.com on MSN6h
Hims & Hers Health shares spike after group posts earnings beat, raises guidanceHims&Hers Health (NYSE:HIMS) reported third-quarter earnings that surpassed analyst expectations and raised its full-year guidance, driven by strong subscriber growth and improving profitability.
5h
TD Cowen analyst Jonna Kim maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of ...
Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback